Rhythm’s drug shows 25% drop in BMI over one year for pa­tients with rare form of obe­si­ty

Rhythm Phar­ma­ceu­ti­cals’ obe­si­ty drug set­melan­otide showed off a 25.5% re­duc­tion in body mass in­dex af­ter 12 months in adult and pe­di­atric pa­tients with hy­po­thal­a­m­ic obe­si­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER